DCVC Bio

Venture Capital investing in companies solving big life science problems with deep tech

[DCVC Bio @DCVCBio]

We're proud to announce DCVC Bio III: $400 million in fresh capital to support great scientific teams with boundary-pushing ideas for curing disease, extending health-spans, enabling healthy food at lower cost and climate impact, and more!
https://t.co/LFbPKsyTBH

[DCVC Bio @DCVCBio]

Read the 2026 Deep Tech Opportunities report → https://t.co/QCX4sZgDZy #DCVCDeepTech

[DCVC Bio @DCVCBio]

Drug discovery has always started with sick patients. @DCVCBio-backed @alchemabtx flips that—sequencing the immune systems of people who carry disease-causing mutations but never get sick, then using AI to turn those signals into life-saving drugs.

Read more below 🧵

[DCVC Bio @DCVCBio]

Great piece from @FierceBiotech on how @UnlearnAI is using digital twins to transform clinical trial decision-making 👇
https://t.co/HC4raPAyBU

[DCVC Bio @DCVCBio]

Exciting progress for Syntax Bio: a research and development collaboration with @MayoClinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes 👏
https://t.co/r0ZfMIuviK

[DCVC Bio @DCVCBio]

Real autonomy, on-field, over-time, with scaled farming businesses relying on its tech. @SabantoAg is 1 of 1.

Great feature in the @nytimes! 👇
https://t.co/huyhpQ0JQk

[BiotechTV @BiotechTV]

𝐂𝐨𝐧𝐯𝐞𝐫𝐠𝐞𝐧𝐜𝐞 𝐅𝐨𝐫𝐮𝐦: Chicago based Grove Biopharma has engineered a technology, Bionic Biologics, that it hopes will give its therapies the versatility of biologics in a small molecule format. #ConvergenceForum

[DCVC Bio @DCVCBio]

Working on hard problems is what @Solu_Tx is working on and has been recognized with #FDA #FastTrackDesignation in #CMML 🥳

[Solu Therapeutics @Solu_Tx]

We are proud to announce that STX-0712, our Phase 1 CCR2-CyTAC™ program in development for patients with resistant/refractory #CMML, has received FDA Fast Track designation. For more information, see our press release: https://t.co/pysnLQPTSo

[Jesse Landry @JesseDLandry]

Gene therapy is moving from promise to precision.

Latus Bio added a $43M Series A extension from @8vc, @DCVCBio, and Hatch BioFund, bringing the round to $97M. P. Peter Ghoroghchian is building an AI-enabled platform focused on precision AAV delivery for neurological disease.

The next biotech edge will come from pairing better vectors with better computational judgment.

[DCVC Bio @DCVCBio]

https://t.co/gvezAOa9Ni

[DCVC Bio @DCVCBio]

At @DCVCBio, we see a need for a massive rein­vest­ment in the search for drugs that safely lessen anxiety, including existing compounds that have been shelved by big pharma companies.

More on our thinking in 🧵

[DCVC Bio @DCVCBio]

https://t.co/VrSClHBkQO

[DCVC Bio @DCVCBio]

RNA- and DNA-based treatments (gene/cell therapy) have high upfront costs but are curative and more economical than chronic care. Regulators should work with insurers and manufacturers to cover costs and introduce new business models, like gradual payment plans.

More in 🧵

[DCVC Bio @DCVCBio]

We’re seeing a new wave of gene therapy companies developing exquisitely customized viral vectors + other advanced techniques that can deliver therapeutic genes to the body with far more specificity and at much lower doses and cost than before. 👇
https://t.co/rQ60ePVpr4

[DCVC Bio @DCVCBio]

In the @WSJ, our friend @crisman_ryan, co-founder of @UmojaBiopharma, offers a beautiful example of basic research meandering through labs over decades, then providing learnings that help us reset the immune systems of leukemia + autoimmune patients:
https://t.co/7CqlRooOuw

[Orca Bio @OrcaBio]

Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025!

This award recognizes the companies and innovations pushing science forward to transform the field of life sciences. We're proud of the work we do on behalf of patients, and honored to be included.

To learn more: https://t.co/eL8G8kLuuN

#FierceLifeSciencesAwards and #FierceInnovationAwards

[Orca Bio @OrcaBio]

Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies.

Read more in the press release: https://t.co/MxbPOkC3HH

#celltherapy #hematology #oncology

[DCVC Bio @DCVCBio]

https://t.co/gBcXwZel1j

[DCVC Bio @DCVCBio]

How is Grove Biopharma archi­tecting its way around traditional drug limits? Learn from @DCVCBio principal Dr. Emily Park and managing partner @2kstead 👇 (link in 🧵)

[DCVC Bio @DCVCBio]

@2kstead https://t.co/8hhMZ7NljV

[DCVC Bio @DCVCBio]

Very exciting progress from Latus Bio! Read more from @DCVCBio Managing Partner @2kstead--link below 👇